Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia

PURPOSE: Inhibition of ribonucleotide reductase reduces the availability of the endogenous pool of deoxycytidine and may increase cytarabine (AraC) cytotoxicity. We performed a phase I dose escalation trial of AraC combined with GTI-2040, a 20-mer antisense oligonucleotide shown in preclinical studi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Klisovic, Rebecca B., Blum, William, Wei, Xiaohui, Liu, Shujun, Liu, Zhongfa, Xie, Zhiliang, Vukosavljevic, Tamara, Kefauver, Cheryl, Huynh, LeNguyen, Pang, Jiuxia, Zwiebel, James A., Devine, Steven, Byrd, John C., Grever, Michael R., Chan, Kenneth, Marcucci, Guido
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2008
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2993318/
https://ncbi.nlm.nih.gov/pubmed/18559610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0109
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk